Unzureichende Rückrufverfolgung und verzögerte Produktrückverfolgung bei Serialisierungsfehlern
Definition
Product recalls require rapid identification of affected batches and transaction history (which wholesaler received which lots, which pharmacies distributed which serials). Manual retrieval of transaction history from distributed systems creates delays, incomplete recall execution, and extended liability windows. Additionally, counterfeit product detection (lack of barcode match in DSCSA database) risks go unidentified until pharmacy-level verification.
Key Findings
- Financial Impact: €50,000–€500,000 per recall incident (estimated: delayed recall costs €100/case × 500–5,000 cases unaccounted for; customer compensation €1,000–€10,000 per pharmacy for disrupted supply; liability exposure for contaminated or counterfeit product distribution).
- Frequency: Incident-based (triggered by manufacturing defects, contamination, or counterfeit detection); industry average 5–15 recalls per year per major wholesaler.
- Root Cause: Manual transaction history compilation; lack of automated product tracing across supply chain network; delayed identification of suspect/illegitimate products at dispensing point.
Why This Matters
This pain point represents a significant opportunity for B2B solutions targeting Wholesale Drugs and Sundries.
Affected Stakeholders
Quality assurance and regulatory affairs, Supply chain and logistics management, Recall coordinators, Customer service and pharmacy liaisons
Deep Analysis (Premium)
Financial Impact
Financial data and detailed analysis available with full access. Unlock to see exact figures, evidence sources, and actionable insights.
Current Workarounds
Financial data and detailed analysis available with full access. Unlock to see exact figures, evidence sources, and actionable insights.
Get Solutions for This Problem
Full report with actionable solutions
- Solutions for this specific pain
- Solutions for all 15 industry pains
- Where to find first clients
- Pricing & launch costs
Methodology & Sources
Data collected via OSINT from regulatory filings, industry audits, and verified case studies.
Evidence Sources:
- https://www.upm-inc.com/serialization-and-aggregation-compliance
- https://www.eawlogistics.com/pharmaceutical-serialization-and-track-and-trace-ensuring-compliance-in-2025/
- https://www.pharma-iq.com/regulatorylegal/articles/dscsa-compliance-strategies-how-business-networks-are-transforming-pharma-logistics
Related Business Risks
Verstoß gegen DSCSA-Serialisierungspflicht und Handelspartnerverfizierung
Manuelle Bottlenecks bei Serialisierungsverifikation und Datenabstimmung
Unvollständige Sichtbarkeit in der Lieferkettendatenintegration und fehlerhaft informierte Geschäftsentscheidungen
Überlast durch manuelle Dokumentation und Mapping
Rückforderungen durch Preisfehler in Großhandelsverträgen
Verzögerte Zahlungen durch Chargeback-Streitigkeiten
Request Deep Analysis
🇩🇪 Be first to access this market's intelligence